

Zurich Open Repository and Archive University of Zurich University Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch

Year: 2023

Optimising success of neonatal extubation: Respiratory support

Gaertner, Vincent D ; Rüegger, Christoph M

Abstract: In this review, we examine lung physiology before, during and after neonatal extubation and propose a three-phase model for the extubation procedure. We perform meta-analyses to compare different modes of non-invasive respiratory support after neonatal extubation and based on the findings, the following clinical recommendations are made.

DOI: https://doi.org/10.1016/j.siny.2023.101491

Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-252666 Journal Article Published Version



The following work is licensed under a Creative Commons: Attribution 4.0 International (CC BY 4.0) License.

Originally published at: Gaertner, Vincent D; Rüegger, Christoph M (2023). Optimising success of neonatal extubation: Respiratory support. Seminars in Fetal Neonatal Medicine, 28(5):101491. DOI: https://doi.org/10.1016/j.siny.2023.101491 Contents lists available at ScienceDirect



Seminars in Fetal and Neonatal Medicine

journal homepage: www.elsevier.com/locate/siny



Optimising success of neonatal extubation: Respiratory support

Vincent D. Gaertner^{a,b}, Christoph M. Rüegger^{a,*}

^a Newborn Research, Department of Neonatology, University Hospital and University of Zürich, Zürich, Switzerland
^b Department of Neonatology, Dr von Hauner Children's Hospital, Ludwig-Maximilians-University Munich, Munich, Germany

ARTICLE INFO

Keywords: Neonatal extubation Non-invasive ventilation Respiratory support Preterm infants

ABSTRACT

In this review, we examine lung physiology before, during and after neonatal extubation and propose a threephase model for the extubation procedure. We perform meta-analyses to compare different modes of noninvasive respiratory support after neonatal extubation and based on the findings, the following clinical recommendations are made:

- 1) Continuous positive airway pressure support (CPAP) remains standard of care for most extubations.
- 2) For high-risk infants <28 weeks' gestation or infants with expected cardiorespiratory instability, either NIPPV or nHFOV may be used as post-extubation respiratory support. Synchronized, ventilator-generated NIPPV may be more effective than alternative modes. The use of nHFOV after extubation seems to confer the largest benefit but clinical experience is limited in most centres.</p>
- 3) If backup CPAP is available, high-flow therapy may be preferred for infants ≥28 weeks with a low fraction of inspired oxygen.

1. Introduction

Non-invasive modes of ventilation are now considered superior to intubation at birth [1]. However, approximately 60 % of preterm infants are intubated in the first days of life, with rates highest in the most immature infants [2]. Prolonged endotracheal ventilation induces inflammation and tissue damage thereby disrupting lung development [3–6]. Thus, clinicians generally aim for early extubation. However, approximately 40 % of very preterm infants develop respiratory failure after extubation and require re-intubation, which in itself is associated with higher mortality rates and significant morbidity, including airway trauma, feeding difficulties and prolonged duration of respiratory support [2,7]. Achieving early, successful extubation is an important challenge for clinicians and researchers.

2. Physiology of neonatal extubation

Neonatal extubation remains a critical phase of a preterm infant's NICU journey. There are several factors contributing to the higher complexity compared with older infants or children, all of which are associated with an increased likelihood of extubation failure: (1) the

upper airway of preterm infants is less stable [8], (2) the lung is more susceptible to collapse [9], (3) functional residual capacity (FRC) and total lung volumes are smaller and therefore, the ability to maintain adequate oxygen levels without respiratory support is poor [10], (4) susceptibility to adverse outcomes due to free oxygen radicals is higher (e.g. retinopathy of prematurity) [11], and (5) the upper respiratory tract is smaller and more fragile, therefore tissue damage is more likely to occur [12].

2.1. Three-phase model of extubation

There are three distinct yet connected phases of neonatal extubation: (1) before extubation, while the infant is still on invasive respiratory support, (2) during extubation, when no respiratory support is provided for a short period, and (3) after extubation, when non-invasive respiratory support is established (Fig. 1).

During phase one, the lung should be adequately recruited, and homogeneously well aerated. The airway is stabilized by the endotracheal tube and continuous distending pressure is guaranteed, thereby maintaining FRC and avoiding atelectasis. This leads to cardiorespiratory stability with stable peripheral oxygen saturation (SpO₂) and heart

https://doi.org/10.1016/j.siny.2023.101491

Available online 18 November 2023

1744-165X/© 2023 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

^{*} Corresponding author: Newborn Research, Department of Neonatology, University Hospital Zurich, Frauenklinikstrasse 10, 8091 Zürich, Switzerland. *E-mail addresses:* vincent.gaertner@med.lmu.de (V.D. Gaertner), christoph.rueegger@usz.ch (C.M. Rüegger).




Fig. 1. Three-phase model of neonatal extubation. Changes in various parameters (A–H) are depicted before, during and after extubation (phases 1–3, respectively). Before extubation, the mean airway pressure is maintained continuously, the upper airway, the lung and the alveoli are stabilized by the positive distending pressure and functional residual capacity (FRC) as well as SpO₂ and heart rate (HR) are kept level. During extubation, a range of physiological changes occur – by taking away the interface and the corresponding positive distending pressure, mean airway pressure decreases, the larynx may collapse, the lung retracts, and alveoli are collapsing. Accordingly, FRC, SpO₂ and HR may decrease, depending on the infant's respiratory stability. Finally, after extubation, the re-initiation of non-invasive respiratory support may assist in recruiting lost lung capacity with an increased mean airway pressure, thereby stabilizing the larynx and collapsed lung tissue including the alveoli.

rate (HR) levels. Stability before extubation is critical in order to proceed into phase two when the risk of atelectasis is substantial.

During phase two, there are major changes in respiratory physiology: The thorax in preterm infants is highly compliant leading to an increased risk of atelectasis. FRC is often lost during the extubation process [13], particularly in the non-gravity-dependent regions of the lung [14]. Tidal volumes immediately after extubation and before the initiation of non-invasive respiratory support are increased compared with pre-extubation, presumably in an attempt to regain lost FRC [14]. "Floppiness" of the upper airway may lead to obstruction during this phase adding to the risk of desaturation and bradycardia [13].

Phase three is characterised by the need to restabilize the respiratory

system after extubation. Immediate application of a continuous positive distending pressure via face mask or nasal prongs is crucial after extubation. This stabilizes the larynx [15], avoiding upper airway obstruction. The positive distending pressure assists in regaining FRC after the loss during phase two [13]. These factors contribute to improvements in cardiorespiratory stability.

It is important to note that this model is most appropriate for more immature infants, as lung physiology is strongly dependent on gestational age and corresponding lung maturity. Immature infants are more susceptible to lung and airway collapse, reducing the likelihood of extubation success [2]. Accordingly, we will provide specific recommendations for different age groups, where appropriate.

3. Clinical data

3.1. Phase one

Signs of readiness for extubation are examined in the chapter of Shalish and Sant'Anna. (Chapter 9)

Preparation for extubation is important to avoid loss of FRC. High quality evidence regarding methods to improve this phase is lacking but we present the following suggestions based on physiological and observational data. A delay in removal of the adhesive tape is responsible for a large loss in FRC [13]. Thus, holding the endotracheal tube in place after adhesive tape removal but before removing the tube may be sensible. Alternatively, cutting the adhesive tape instead of removing it entirely in this sensitive phase may prevent further FRC loss before extubation. Minimal handling and pain-reducing sucrose administration may improve cardiorespiratory stability, thereby reducing the severity of desaturation and bradycardia [16]. Many centres routinely perform endotracheal suctioning before extubation. A small study has shown that lung volumes remained similar after endotracheal suctioning [13], but it may clear secretions from the airways, thereby reducing the risk of obstruction. Pre-oxygenation is routinely performed in older infants and children to facilitate a more stable transition to non-invasive respiratory support. However, there is evidence to suggest an increased susceptibility to free oxygen radicals and subsequent longer-term clinical harm in preterm infants [11]. We speculate that a higher FRC before initiation of extubation may provide a larger reserve and more overall stability. Accordingly, increasing the mean airway pressure before extubation or performing an "inspiratory hold" procedure (where the ventilator maintains the inspiratory pressure for the duration of the extubation), may increase lung volumes and provide increased stability. However, large pressures may also be injurious to the lung and no study to date has investigated this procedure. Therefore, we are not recommending the routine use of either pre-oxygenation or an inspiratory hold. As the dorsal aspect of the lung is larger than the ventral aspect due to the steep angle of diaphragmatic insertion at the rib cage, extubation in prone position may improve baseline FRC levels. None of these factors has been evaluated in rigorous studies with relevant clinical outcomes and thus, their clinical effects remain unknown.

3.2. Phase two

To our knowledge, there are no clinical studies evaluating respiratory support during the extubation procedure in preterm infants and thus, there is no evidence how to manage the phase immediately following extubation. However, from a physiological standpoint, continued respiratory support with a positive distending pressure (i.e. *PrePAP*) may prevent the loss of FRC and may assist in maintaining cardiorespiratory stability during extubation [13].

Worldwide, most preterm infants are intubated orally where a positive distending pressure may be provided throughout the extubation procedure via nasal prongs placed before extubation. This may help to maintain lung volumes and to avoid handling during the potentially unstable immediate post-extubation period. In most European countries, nasal intubation is common practice. In these infants, the endotracheal tube may be pulled back only marginally after extubation, thus keeping it in place as a nasopharyngeal tube temporarily until successful transition to non-invasive ventilation. The switch to a nasal mask/prongs can then be performed during the next round of care, possibly allowing the infant to stabilize before switching to an alternative interface. Finally, nasal/oral suctioning after extubation is controversial: On the one hand, it may decrease airway obstruction. Conversely, it may increase the time until non-invasive respiratory support is initiated, thereby potentially contributing to a larger loss in FRC. However, data are scarce and randomized controlled trials are needed to evaluate these ideas in the clinical setting.

3.3. Phase three

Nasal continuous positive airway pressure (CPAP) has become the standard of care for post-extubation respiratory support of preterm infants. CPAP maintains alveolar recruitment, prevents atelectasis, and reduces ventilation-perfusion mismatch, which improves oxygenation and work of breathing. As a result, CPAP reduces the incidence of respiratory failure among preterm infants after extubation without clinically important side effects [17].

Despite its physiological and clinical benefits, half of extremely preterm infants supported with CPAP after extubation require reintubation [18], which has been shown to be independently associated with adverse outcomes including a higher mortality before discharge, prolonged respiratory support, and hospitalization [19]. Therefore, methods to increase the effectiveness of post-extubation respiratory support have gained interest over the last years [20].

Non-invasive intermittent positive pressure ventilation (NIPPV) combines a continuous positive end-expiratory pressure (PEEP) with intermittent higher pressures delivered by nasal mask or nasal prongs. Two NIPPV modalities should be distinguished. On the one hand, there is traditional NIPPV, with settings designed to mimic ventilator settings. On the other hand, there are settings which are more reflective of bilevel CPAP, typically generated using flow-drivers [21]. Both devices are able to synchronize pressure changes with spontaneous breathing. Most commonly, Graseby capsules are used for NIPPV synchronisation but other options exist [22]. Neurally adjusted ventilator assist (NAVA) uses the electrical activity of the patient's diaphragm as a trigger to deliver synchronized inflations proportional to the infant's inspiratory effort [23].

Nasal high-flow therapy (hereafter, high-flow therapy) is an increasingly popular alternative to CPAP. During high-flow therapy, heated, humidified gas is delivered through narrow nasal cannulae. These appear to be more comfortable for infants than CPAP and NIPPV [24]. Commonly, gas flows greater than 2 L/min (e.g. 2–8 L/min) are used. With flows greater than 4 L/min, distending pressures are similar to those set with CPAP [25]. In contrast to CPAP, positive distending pressures generated during high-flow therapy are not measured and may be variable.

Non-invasive high-frequency oscillatory ventilation (nHFOV) is a relatively new method of augmenting CPAP support in preterm infants. Generated by a mechanical ventilator and transmitted via a nasal interface, it applies continuous airway pressures with superimposed oscillations during spontaneous breathing [26]. Electrical impedance tomography recordings demonstrate that these oscillations are transmitted to the lungs [27]. Thus, nHFOV could provide the advantages of both invasive high frequency oscillatory ventilation and CPAP. Surveys show that nHFOV is being used in clinical care in some European centres [28].

There is considerable uncertainty regarding the optimal non-invasive technique to support preterm infants after mechanical ventilation leading to a wide variability in clinical practice. The following metaanalyses will summarize the current evidence on the best form of respiratory support after extubation by examining data from RCTs

Table 1

Randomized controlled trials included in the meta-analyses.

| Study | Patients [n] | GA [wk] | Comparisons | Primary outcomes | Enrolled population |
|--|--------------|---------|--------------------------|-----------------------|--|
| 1.1.1. Nonsynchronized NIPPV vs | CPAP | | | | |
| Khorana 2008 [37] | 48 | NDA | NIPPV vs CPAP | Reintubation <7 days | VLBW infants with RDS |
| O'Brien 2012 [38] | 136 | 27.4 | BiPAP vs CPAP | Reintubation <7 days | Infants <1250 g with RDS |
| Kahramaner 2014 [39] | 67 | 28.8 | NIPPV vs CPAP | Reintubation <48 h | Infants (<35 wks, <2000 g) with RD |
| Jasani 2016 [40] | 63 | 30.7 | NIPPV vs CPAP | Reintubation <72 h | VLBW infants with RDS |
| Komatsu 2016 [41] | 72 | 30.8 | NIPPV vs CPAP | Reintubation <72 h | Infants (\leq 36 wks, $>$ 750 g) |
| Victor 2016 [42] | 540 | 27.3 | BiPAP vs CPAP | Reintubation <48 h | Preterm infants <30 wks |
| Esmaeilnia 2016 [43] | 150 | 32.1 | NIPPV vs CPAP | Reintubation <72 h | Preterm infants after INSURE |
| | 101 | 29.6 | NIPPV vs CPAP | Reintubation <48 h | |
| Ribeiro 2017 [44] | 220 | 29.0 | NIPPV VS CPAP | Reintubation <72 h | Infants (<34 wks, <1500 g) with RD |
| Estay 2020 [45] | | | | | VLBW infants with RDS |
| Pan 2021 [46] | 284 | 29.9 | BiPAP vs CPAP | Reintubation <72 h | Infants <1500 g after INSURE |
| Li 2021 [47] | 94 | NDA | NIPPV vs CPAP (vs nHFOV) | Reintubation <7 days | Preterm Infants $25 + 0-33 + 6$ wks |
| Zhu 2022 [31] | 960 | 29.5 | NIPPV vs CPAP (vs nHFOV) | Total duration of IMV | Preterm infants $25 + 0 - 32 + 6$ wks |
| Yuan 2022 [48] | 80 | 30.4 | NIPPV vs CPAP (vs nHFOV) | Reintubation <72 h | Preterm infants with RDS |
| El-Farrash 2022 [49] | 120 | 32.6 | NIPPV vs BiPAP vs CPAP | Reintubation <48 h | Preterm infants \leq 35 wks with RDS |
| 1.1.2. Synchronized NIPPV vs CPA | | | | | |
| Friedlich 1999 [50] | 41 | 27.8 | sNIPPV vs CPAP | Reintubation <48 h | VLBW infants with RDS |
| Barrington 2001 [51] | 54 | 26.3 | sNIPPV vs CPAP | Reintubation <72 h | Preterm infants ≤ 1250 g |
| Khalaf 2001 [52] | 64 | 28.0 | sNIPPV vs CPAP | Reintubation <72 h | Preterm infants \leq 34 wks with RDS |
| Moretti 2008 [53] | 63 | 27.0 | sNIPPV vs CPAP | Reintubation <72 h | VLBW infants with RDS |
| Gao 2010 [54] | 50 | 32.5 | sNIPPV vs CPAP | NDA | Preterm infants with RDS |
| Ding 2020 [55] | 120 | 29.6 | sNIPPV vs CPAP | Reintubation <72 h | Preterm infants (<32 wks, <1250 g) |
| Shin 2022 [56] | 78 | 26.9 | NIV-NAVA vs CPAP | Reintubation <72 h | Preterm infants <30 wks |
| 1.1.3. NIPPV (mixed methods) vs | CPAP | | | | |
| Kirpalani 2013 [57] | 845 | 26.2 | NIPPV/sNIPPV vs CPAP | Death/BPD <36 wks | Preterm infants (<30 wks, <1000g) |
| 2.1.1. High-flow vs CPAP, < 28 w | | | | , | |
| Collins 2013 [58] | 59 | NDA | High-flow vs CPAP | Reintubation <7 days | Preterm infants <32 wks |
| Manley 2013 [59] | 174 | NDA | High-flow vs CPAP | Reintubation <7 days | Preterm infants <32 wks |
| Soonsawad 2017 [60] | 29 | NDA | High-flow vs CPAP | Reintubation <72 h | Preterm infants <32 wks |
| Elkhwad 2017 [61] | 43 | 26.8 | High-flow vs CPAP | Reintubation <5 days | Preterm infants 24–28 wks |
| | | 20.0 | Tilgii-llow VS CFAF | Reliftubation <5 days | Ficterini iniants 24–20 wks |
| 2.1.2. High-flow vs CPAP, ≥ 28 we | | 97 F | High flow we CDAD | Dointybotion 7 down | Dustant infonts <1000 a |
| Campbell 2006 [62] | 40 | 27.5 | High-flow vs CPAP | Reintubation <7 days | Preterm infants ≤1250 g |
| Collins 2013 [58] | 73 | NDA | High-flow vs CPAP | Reintubation <7 days | Preterm infants <32 wks |
| Manley 2013 [59] | 129 | NDA | High-flow vs CPAP | Reintubation <7 days | Preterm infants <32 wks |
| Yoder 2013 [63] | 432 | 33.4 | High-flow vs CPAP | Reintubation <72 h | Infants ≥ 28 wks |
| Mostafa-Gharehbaghi 2014 [64] | 85 | 32.2 | High-flow vs CPAP | Reintubation <72 h | Preterm infants (30–34 wks) |
| Liu 2014 [65] | 255 | 35.5 | High-flow vs CPAP | Reintubation <7 days | Preterm infants postextubation |
| Chen 2015 [66] | 66 | 32.5 | High-flow vs CPAP | Reintubation <7 days | VLBW infants with RDS |
| Soonsawad 2017 [60] | 20 | NDA | High-flow vs CPAP | Reintubation <72 h | Preterm infants <32 wks |
| Kadivar 2021 [67] | 90 | NDA | High-flow vs CPAP | Reintubation <72 h | Preterm infants after INSURE |
| Singh2022 [68] | 30 | 30 | High-flow vs CPAP | Reintubation <7 days | Preterm infants after INSURE |
| 2.1.3. High-flow vs CPAP, mixed 1 | nethods | | | | |
| Kang 2016 [69] | 161 | NDA | High-flow vs CPAP | Reintubation <7 days | Preterm infants (30-32 wks) |
| Chen 2020 [70] | 94 | 27.4 | High-flow vs CPAP | Reintubation <72 h | VLBW infants with RDS |
| Uchiyama 2020 [71] | 372 | 28.3 | High-flow vs CPAP/NIPPV | Reintubation <7 days | Preterm infants <34 wks |
| 3.1.1. nHFOV vs CPAP | | | 5 | | |
| Lou 2017 [72] | 65 | 32.5 | nHFOV vs CPAP | Reintubation <7 days | Preterm infants with RDS |
| Chen 2019 [73] | 206 | 32.6 | nHFOV vs CPAP | Reintubation <7 days | Preterm infants <37 wks |
| .i 2021 [47] | 92 | NDA | nHFOV vs CPAP | Reintubation <7 days | Preterm infants (25–34 wks) |
| (uan 2022 [48] | 80 | 30.3 | nHFOV vs CPAP (vs NIPPV) | Reintubation <72 h | Preterm infants with RDS |
| Chu 2022 [31] | 960 | 29.4 | nHFOV vs CPAP (vs NIPPV) | Total duration of IMV | Preterm infants 25–33 wks |
| | 500 | 27.4 | mirov vs GrAP (vs NiPPV) | | 110001111 111101103 23-33 WKS |
| 4.1.1. nHFOV vs NIPPV | 102 | 20.7 | THEON IN MIDDLY | Deintubetion 170 h | VI DW infonto with DDC |
| Wang 2019 [74] | 103 | 29.7 | nHFOV vs NIPPV | Reintubation <72 h | VLBW infants with RDS |
| Seth 2021 [75] | 86 | 32 | nHFOV vs NIPPV | Reintubation <72 h | Preterm infants 26–37 wks |
| lia 2021 [76] | 100 | 31.9 | nHFOV vs NIPPV | Reintubation <72 h | Preterm infants with LBW |
| Zhuang 2021 [77] | 90 | 29 | nHFOV vs NIPPV | Reintubation <72 h | Preterm infants with severe BPD |
| Li 2021 [47] | 92 | 29 | nHFOV vs NIPPV | Reintubation <7 days | Preterm infants (25-34 wks) |
| ruan 2022 [48] | 80 | 30.5 | nHFOV vs NIPPV (vs CPAP) | Reintubation <72 h | Preterm infants with RDS |
| Zhu 2022 [31] | 960 | 29.4 | nHFOV vs NIPPV (vs CPAP) | Total duration of IMV | Preterm infants 25 + 0-32 + 6 wks |
| Zhang 2022 [78] | 41 | 35 | nHFOV vs NIPPV | Reintubation <72 h | Preterm infants with PPHN |

NDA: no data available, VLBW: very low birth weight, RDS: respiratory distress syndrome, Wks: weeks, INSURE: intubation – surfactant – extubation, LBW: low birth weight, NIV-NAVA: Noninvasive Neurally Adjusted Ventilatory Assist, BPD: bronchopulmonary dysplasia, PPHN: persistent pulmonary hypertension of the newborn.

comparing NIPPV, high-flow therapy and nHFOV as potential alternatives to CPAP for preterm infants after extubation.

4. Meta-analyses of trials for post-extubation respiratory support

A literature search was performed of PubMed, The Cochrane Library, and the reference lists of included articles. The search combined the individual form of respiratory support (see below) with the following terms: *preterm infant* and *extubation*. RCTs that enrolled preterm infants (born <37 weeks' gestation) and compared the following techniques were included.

- NIPPV (traditional NIPPV, bilevel CPAP, NIV-NAVA) versus CPAP
- Nasal high-flow versus CPAP
- nHFOV versus CPAP
- nHFOV versus NIPPV (traditional NIPPV, bilevel CPAP, NIV-NAVA)

| | NIPPV | СРА | Р | | Risk Ratio | | Risk Ratio |
|---|------------------------|-------------------------------|------------|----------------|--|------|---|
| Study or Subgroup | | otal Events | Total | Weight | M-H, Random, 95% CI | Year | M-H, Random, 95% Cl |
| 1.1.1 NIPPV, non-syn | chronized | | | | | | |
| Khorana 2008 | 2 | 24 4 | 24 | 1.5% | 0.50 [0.10, 2.48] | | |
| O'Brien 2012 | 22 | 67 29 | 69 | 7.5% | 0.78 [0.50, 1.21] | | |
| Kahramaner 2014 | 5 | 39 10 | 28 | 3.4% | 0.36 [0.14, 0.94] | | |
| Jasani 2016 | 6 | 31 9 | 32 | 3.7% | 0.69 [0.28, 1.70] | | |
| Komatsu 2016 | 6 | 36 11 | 36 | 3.8% | 0.55 [0.23, 1.32] | | |
| Victor 2016 | | 270 85 | 270 | 9.6% | 1.08 [0.85, 1.38] | | T |
| Esmaeilnia 2016 | 5 | 77 13 | 73 | 3.3% | 0.36 [0.14, 0.97] | | |
| Ribeiro 2017 | 5 | 36 15 | 65 | 3.6% | 0.60 [0.24, 1.52] | | |
| Estay 2020 | | 112 35 144 21 | 108 | 8.1% 5.8% | 0.99 [0.68, 1.45] | | |
| Pan 2021 Li 2021 | 16 1 12 | 47 25 | 140 | | 0.74 [0.40, 1.36] | | |
| Zhu 2022 | | 47 25 480 97 | 47 480 | 6.3% 8.9% | 0.48 [0.27, 0.84] 0.57 [0.42, 0.77] | | |
| Yuan 2022 | 10 | 80 25 | 480 | 5.3% | 0.37 [0.42, 0.77] | | |
| El-Farrash 2022 | 8 | 80 23 80 3 | 40 | 2.2% | 1.33 [0.37, 4.75] | | - |
| Subtotal (95% CI) | - | 523 | 1492 | 73.0% | 0.67 [0.53, 0.84] | 2022 | • |
| Total events | 280 | 382 | | | | | • |
| Heterogeneity: Tau ² = | 0.08; Chi ² | = 26.45, df = | = 13 (P | = 0.01); | $l^2 = 51\%$ | | |
| Test for overall effect: | Z = 3.45 (P | 9 = 0.0006) | | | | | |
| 1.1.2 NIPPV, synchro | nized | | | | | | |
| Friedlich 1999 | 1 | 22 7 | 19 | 1.0% | 0.12 [0.02, 0.91] | 1999 | |
| Barrington 2001 | 4 | 27 12 | 27 | 3.2% | 0.33 [0.12, 0.90] | 2001 | |
| Khalaf 2001 | 2 | 34 12 | 30 | 1.9% | 0.15 [0.04, 0.60] | 2001 | |
| Moretti 2008 | 2 | 32 12 | 31 | 1.9% | 0.16 [0.04, 0.66] | 2008 | |
| Gao 2010 | 6 | 25 15 | 25 | 4.5% | 0.40 [0.19, 0.86] | | |
| Ding 2020 | 2 | 40 10 | 40 | 1.8% | 0.20 [0.05, 0.86] | | |
| Shin 2022 | 3 | 35 10 | 35 | 2.4% | 0.30 [0.09, 1.00] | 2022 | |
| Subtotal (95% CI) | | 215 | 207 | 16.8% | 0.27 [0.18, 0.42] | | • |
| Total events Heterogeneity: Tau ² = | 20 | 78 2 24 df | 6 (D | 0 76) 12 | 00/ | | |
| Test for overall effect: | , | , | 0 (P = | 0.76), 1 = | = 0% | | |
| 1.1.3 Mixed Methods | | | | | | | |
| Kirpalani 2013 | | 423 182 | 422 | 10.2% | 0.86 [0.72, 1.01] | 2012 | - |
| Subtotal (95% CI) | | 1 23 182 123 | 422 422 | 10.2% 10.2% | 0.86 [0.72, 1.01] 0.86 [0.72, 1.01] | 2015 | • |
| Total events | 156 | 182 | | | | | |
| Heterogeneity: Not ap Test for overall effect: | · | 9 = 0.06) | | | | | |
| Total (95% CI) | 21 | 161 | 2121 | 100.0% | 0.58 [0.47, 0.72] | | • |
| Total events | 456 | 642 | | | | | |
| Heterogeneity: Tau ² = Test for overall effect: Test for subgroup diff | Z = 5.00 (P | < 0.00001) | | | | 0.0 | 01 0.1 1 10 100 Favours NIPPV Favours CPAP |

Fig. 2. Forest plot comparing NIPPV versus CPAP for post-extubation respiratory support (by synchronisation).

Data from included trials were extracted and cross-verified independently by the two authors of this review. Subgroup analyses were performed for the primary outcome by synchronisation (for the comparison NIPPV versus CPAP) and by gestational age at birth (for the comparison nasal high-flow versus CPAP). The primary outcome was defined as extubation failure (leading to additional ventilatory support/ reintubation) within the first seven days post-extubation. Trials that reported extubation failure within a shorter time frame (e.g. within 72 h after extubation) or evaluated post-extubation respiratory support strategies after the INSURE (intubation – surfactant – extubation) procedure were included in the analysis. Publications in non-English languages were translated using Google translator. Meta-analyses were performed with RevMan (version 5.3) [29] using a random-effect model to pool data of included trials. Information on included trials is provided in Table 1.

4.1. NIPPV versus CPAP

We pooled data from 22 trials and 4282 preterm infants comparing

NIPPV versus CPAP used as post-extubation respiratory support. Eleven of these trials reported a significant reduction in rates of respiratory failure in infants managed with NIPPV and the other 11 showed no difference between groups. In 14 trials, non-synchronized NIPPV was used. Seven trials applied NIPPV in a synchronized manner, and in one study, mixed methods were used. Since publication of the last Cochrane Review, twelve additional RCTs enrolling 2851 infants have addressed this question [30].

Overall, infants extubated to NIPPV had significantly lower rates of respiratory failure within the first week after extubation compared with those managed with CPAP, with a number needed to treat of 11 infants (combined subgroups 1.1.1, 1.1.2, and 1.1.3: RR 0.58, 95 % CI 0.47 to 0.72; RD -0.13, 95 % CI -0.17 to -0.08; Fig. 2). This beneficial effect was most obvious in the trials using synchronized NIPPV (subgroup 1.1.2: RR 0.27, 95 % CI 0.18 to 0.42; RD -0.27, 95 % CI -0.35 to -0.20). On average, only four infants would need to be extubated to synchronized NIPPV to prevent one extubation failure.

Irrespective of the NIPPV mode that was used, it is important to understand that the level of support differs considerably between

| Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl Year M-H, Random, 95% Cl 2.1.1 Respiratory failure, <28 weeks 5 5 0.71 [0.39, 1.28] 2013 0.71 [0.39, 1.28] 2016 0.71 [0.39, 1.28] 2016 0.71 [0.39, 1.28] 2017 5.75 [0.30, 1.19] 0.75 [0.30, 1.19] < |
|---|
| Collins 2013 11 30 15 29 7.6% 0.71 [0.39, 1.28] 2013 Manley 2013 43 83 32 91 10.2% 1.47 [1.04, 2.09] 2013 Soonsawad 2017 6 14 4 15 4.2% 1.61 [0.57, 4.52] 2016 Elkhwad 2017 5 19 5 24 3.9% 1.26 [0.43, 3.73] 2017 Subtotal (95% Cl) 146 159 26.0% 1.19 [0.79, 1.79] Image: Constant of the second se |
| Manley 2013 43 83 32 91 10.2% 1.47 [1.04, 2.09] 2013 Soonsawad 2017 6 14 4 15 4.2% 1.61 [0.57, 4.52] 2016 Elkhwad 2017 5 19 5 24 3.9% 1.26 [0.43, 3.73] 2017 Subtotal (95% Cl) 146 159 26.0% 1.19 [0.79, 1.79] Image: Close of the second s |
| Soonsawad 2017 6 14 4 15 4.2% 1.61 [0.57, 4.52] 2016 Elkhwad 2017 5 19 5 24 3.9% 1.26 [0.43, 3.73] 2017 Subtotal (95% Cl) 146 159 26.0% 1.19 [0.79, 1.79] Image: Close of the second seco |
| Elkhwad 2017 5 19 5 24 3.9% 1.26 [0.43, 3.73] 2017 Subtotal (95% Cl) 146 159 26.0% 1.19 [0.79, 1.79] Image: the second se |
| Subtotal (95% CI) 146 159 26.0% 1.19 [0.79, 1.79] Total events 65 56 |
| Total events 65 56 |
| |
| Heterogeneity: $Tau^2 = 0.06$; $Chi^2 = 4.67$, $df = 3$ (P = 0.20); $I^2 = 36\%$ |
| Test for overall effect: $Z = 0.81$ (P = 0.42) |
| 2.1.2 Respiratory failure, ≥28 weeks |
| Campbell 2006 12 20 3 20 3.8% 4.00 [1.33, 12.05] 2006 |
| Manley 2013 9 69 7 60 4.8% 1.12 [0.44, 2.82] 2013 |
| Yoder 2013 11 107 9 119 5.4% 1.36 [0.59, 3.15] 2013 |
| Collins 2013 4 37 7 36 3.7% 0.56 [0.18, 1.74] 2013 |
| Liu 2014 12 128 12 127 6.0% 0.99 [0.46, 2.12] 2014 |
| Mostafa-Gharehbaghi 2014 5 42 8 43 4.2% 0.64 [0.23, 1.80] 2014 - |
| Chen 2015 16 32 10 34 7.3% 1.70 [0.91, 3.18] 2015 |
| Kadivar 2016 14 27 4 27 4.5% 3.50 [1.32, 9.28] 2016 |
| Soonsawad 2017 2 10 2 10 1.9% 1.00 [0.17, 5.77] 2016 |
| Yengkhom 2021 14 63 12 65 6.7% 1.20 [0.60, 2.40] 2021 |
| Singh 2022 10 30 5 15 5.2% 1.00 [0.42, 2.40] 2022 Subtotal (95% CI) 565 556 53.5% 1.31 [0.95, 1.80] Image: Comparison of the second sec |
| Total events 109 79 |
| Heterogeneity: Tau ² = 0.08; Chi ² = 13.67, df = 10 (P = 0.19); $I^2 = 27\%$ |
| Test for overall effect: $Z = 1.65$ (P = 0.10) |
| 2.1.3 Respiratory failure, mixed GA |
| Kang 2016 11 79 10 82 5.7% 1.14 [0.51, 2.54] 2016 |
| Chen 2020 11 48 11 46 6.3% 0.96 [0.46, 1.99] 2020 |
| Uchiyama 2020 54 176 17 196 8.5% 3.54 [2.13, 5.87] 2020 |
| Subtotal (95% CI) 303 324 20.5% 1.63 [0.66, 4.01] |
| Total events 76 38 |
| Heterogeneity: $Tau^2 = 0.51$; $Chi^2 = 10.78$, $df = 2$ (P = 0.005); $I^2 = 81\%$ |
| Test for overall effect: $Z = 1.06 (P = 0.29)$ |
| Total (95% CI) 1014 1039 100.0% 1.35 [1.04, 1.74] |
| Total events 250 173 |
| Heterogeneity: $Tau^2 = 0.14$; $Chi^2 = 33.69$, $df = 17$ (P = 0.009); $I^2 = 50\%$ Test for everyll effort: $7 = 2.24$ (P = 0.02) |
| Test for overall effect: Z = 2.24 (P = 0.03) |
| Test for subgroup differences: Chi ² = 0.43, df = 2 (P = 0.81), $I^2 = 0\%$ |

Fig. 3. Forest plot comparing high-flow therapy versus CPAP for post-extubation support (by gestational age).

ventilator-generated and flow-driver-generated NIPPV. We demonstrated previously that ventilator-generated synchronized NIPPV is most effective to prevent respiratory failure after extubation [21].

4.2. Nasal high-flow versus CPAP

In preterm infants, high-flow therapy for post-extubation respiratory support has been evaluated in 15 trials and 1948 infants. Since the 2016 Cochrane Review, ten additional RCTs including 1162 preterm infants have examined the efficacy of high-flow therapy to prevent extubation failure [24]. Four trials found a significant increase in rates of respiratory failure with high-flow therapy and no trial reported a significant reduction in respiratory failure with high-flow therapy.

Pooled data from all 15 trials demonstrated an increase in the risk of respiratory failure when infants were extubated to high-flow therapy (combined subgroups 2.1.1, 2.1.2, and 2.1.3: RR 1.35, 95 % CI 1.04 to 1.74; RD 0.07, 95 % CI 0.01 to 0.13; Fig. 3). In both subgroups (infants <28 and \geq 28 weeks' gestation), there was no significant difference between high-flow therapy and CPAP in the rate of treatment failure after extubation (Fig. 3).




Fig. 4. Forest plot comparing nHFOV versus CPAP for post-extubation respiratory support.

| | nHFC | ov. | NIPP | v | | Risk Ratio | | Risk Ratio |
|---|--------|-------|--------|-------|----------|---------------------|------|-----------------------------|
| Study or Subgroup | Events | Total | Events | Total | Weight M | M-H, Random, 95% CI | Year | M-H, Random, 95% Cl |
| Wang 2019 | 5 | 50 | 14 | 53 | 7.7% | 0.38 [0.15, 0.97] | 2019 | |
| Zhuang 2021 | 10 | 45 | 15 | 45 | 14.7% | 0.67 [0.34, 1.32] | 2021 | |
| Li 2021 | 7 | 50 | 16 | 50 | 10.8% | 0.44 [0.20, 0.97] | 2021 | |
| Seth 2021 | 4 | 43 | 5 | 43 | 4.4% | 0.80 [0.23, 2.78] | 2021 | |
| Jia 2021 | 1 | 50 | 2 | 50 | 1.2% | 0.50 [0.05, 5.34] | 2021 | · · · · · |
| Zhu 2022 | 43 | 480 | 55 | 480 | 48.1% | 0.78 [0.54, 1.14] | 2022 | |
| Zhang 2022 | 3 | 19 | 5 | 22 | 4.1% | 0.69 [0.19, 2.53] | 2022 | |
| Yuan 2022 | 8 | 80 | 10 | 80 | 9.0% | 0.80 [0.33, 1.92] | 2022 | |
| Total (95% CI) | | 817 | | 823 | 100.0% | 0.67 [0.52, 0.88] | | • |
| Total events 81 122 Heterogeneity: Tau ² = 0.00; Chi ² = 3.44, df = 7 (P = 0.84); I ² = 0% Test for overall effect: Z = 2.96 (P = 0.003) | | | | | | 0% | | |
| | | | | | | | | Favours nHFOV Favours NIPPV |

Fig. 5. Forest plot comparing nHFOV versus NIPPV for post-extubation respiratory support.

In most of the included trials, the use of rescue CPAP/NIPPV was permitted for infants meeting treatment failure criteria during high-flow therapy. Rescue CPAP/NIPPV has been shown to prevent a significant number of re-intubations in infants between 28 and 32 weeks' gestation with treatment failure under high-flow therapy (RR 0.51; 95 % CI, 0.27–0.97; 5 studies, 382 infants) [24].

4.3. nHFOV versus CPAP

Results from five trials enrolling 1483 infants were pooled for this analysis. All five individual trials reported a beneficial effect when nHFOV was used to avoid treatment failure after extubation. Overall, infants extubated to nHFOV had significantly lower rates of respiratory failure within the first week after extubation compared with those managed with CPAP (RR 0.41, 95 % CI 0.30 to 0.56; RD -0.22, 95 % CI -0.32 to -0.12, Fig. 4). Compared with CPAP, only six infants need to be treated with nHFOV after extubation to prevent one respiratory failure.

Of the five RCTs included in this comparison, the trial by Zhu et al. dominates the literature [31]. The multicentre NASal OscillatioN post-Extubation (NASONE) trial was conducted in 69 neonatal intensive care units in China. Preterm infants between 25 plus 0 days and 32 plus 6 days ready to be extubated were randomized to receive CPAP, NIPPV or nHFOV until discharge. Among 1440 preterm neonates with a mean gestational age of 29.4 weeks at birth, 497 were allocated to nHFOV, 480 of whom were included in the final analysis. Compared with CPAP, nHFOV halved the need for invasive respiratory support when used after extubation (reintubation rate: nHFOV 13.1 % versus CPAP 25.6 %; p-value <0.001).

4.4. nHFOV versus NIPPV

Since nHFOV is commonly regarded as rescue intervention in infants failing conventional non-invasive respiratory support such as NIPPV, we appended our updated meta-analyses with a direct comparison between nHFOV and NIPPV for preterm infants after extubation. We identified eight trials including 1640 preterm infants for the pooled analysis. Two trials reported a significant benefit for nHFOV, and six trials showed no significant difference between the two modalities. Of note, nonsynchronized NIPPV was used in two trials. In the remaining six trials, exact methods could not be ascertained.

Pooled data demonstrated that infants extubated to nHFOV had a significantly lower risk for respiratory failure compared with infants extubated to NIPPV (RR 0.67, 95 % CI 0.52 to 0.88; RD -0.04, 95 % CI -0.08 to -0.01; Fig. 5). Extubation of 20 infants to nHFOV would prevent one case of extubation failure. Again, meta-analysis was dominated by the results of the NASONE trial. Although fewer infants failed their allocated therapy in the nHFOV group compared with the NIPPV group, this difference was not statistically significant (reintubation rate:

nHFOV 13.1 % versus NIPPV 17.5 %; p-value 0.07).

4.5. Positive end-expiratory pressure after extubation

From a physiological perspective, a higher end-expiratory pressure may re-recruit lost FRC and prevent additional alveolar collapse more effectively than a lower pressure [32]. The as yet unpublished Extubation CPAP Level Assessment Trial (ECLAT) compared the effect of higher CPAP pressures of 9–11 cm H₂O with current standard pressures of 6–8 cm H₂O on extubation failure. The initial recruitment target of 200 extremely preterm infants was not reached; the trial was stopped early after 138 infants due to difficulties in recruitment [33]. Despite the smaller sample size, the authors demonstrated that extubation to higher CPAP pressures reduced the risk of extubation failure compared with the standard pressure range (35 % vs 57 %; risk difference –0.22, 95 % CI -0.37 to –0.04). There were no important differences in any of the safety outcomes [34]. Based on these results, higher CPAP pressures may be beneficial for extubation of extremely preterm infants.

4.6. Safety

CPAP has been used as primary respiratory support and as postextubation support for several decades now and there is ample clinical data supporting its safety. The other modes of respiratory support have also not been associated with important adverse effects. In two systematic reviews comparing NIPPV with CPAP as primary respiratory support and as post-extubation support, no differences in rates of feeding intolerance, gastrointestinal perforation, necrotizing enterocolitis, or air leak were identified [30,35]. The recent NASONE trial also showed that nHFOV, NIPPV and CPAP were equally safe in a large population of very preterm infants [31]. Nasal trauma occurred slightly less often during high-flow therapy than with alternative means of respiratory support [24].

5. What's next for post-extubation support in preterm infants

While many respiratory support strategies before, during and after extubation have been investigated, there are still many open questions for clinicians and researchers. We suggest that future trials should answer the following questions in order to improve extubation outcomes of preterm infants:

Pre-extubation.

- 1) Pre-oxygenation in preterm infants to determine the optimal safe and effective SpO₂ target range
- 2) Evaluation of the ideal pre-extubation mean airway pressure (e.g. using higher MAPs to recruit the lung before extubation)

V.D. Gaertner and C.M. Rüegger

| Compai | rator | СРА | Р | Risk Ratio | Risk | Ratio |
|--------|---|--|---|---|--|---|
| Events | Total | Events | Total | M-H, Random, 95% CI | M-H, Rand | om, 95% Cl |
| | | | | | | |
| 456 | 2161 | 642 | 2121 | 0.70 [0.63, 0.77] | + | |
| 280 | 1523 | 382 | 1492 | 0.72 [0.63, 0.82] | + | |
| 20 | 215 | 78 | 207 | 0.25 [0.16, 0.39] | — — | |
| 156 | 423 | 182 | 422 | 0.86 [0.72, 1.01] | + | - |
| | | | | | | |
| 250 | 1014 | 173 | 1039 | 1.48 [1.24, 1.76] | | + |
| 65 | 146 | 56 | 159 | 1.26 [0.96, 1.67] | | ├- ╋ |
| 109 | 565 | 79 | 556 | 1.36 [1.04, 1.77] | | — — |
| 76 | 303 | 38 | 324 | 2.14 [1.50, 3.05] | | |
| | | | | | | |
| 96 | 742 | 220 | 741 | 0.44 [0.35, 0.54] | -+ | |
| | | | | | | |
| | | | | | | |
| | Events 456 280 20 156 250 65 109 76 | 456 2161 280 1523 20 215 156 423 250 1014 65 146 109 565 76 303 | Events Total Events 456 2161 642 280 1523 382 20 215 78 156 423 182 250 1014 173 65 146 56 109 565 79 76 303 38 | EventsTotalEventsTotal45621616422121280152338214922021578207156423182422250101417310396514656159109565795567630338324 | EventsTotalEventsTotalM-H, Random, 95% Cl456216164221210.70 [0.63, 0.77]280152338214920.72 [0.63, 0.82]20215782070.25 [0.16, 0.39]1564231824220.86 [0.72, 1.01]250101417310391.48 [1.24, 1.76]65146561591.26 [0.96, 1.67]109565795561.36 [1.04, 1.77]76303383242.14 [1.50, 3.05] | Events Total Events Total M-H, Random, 95% CI M-H, Random 456 2161 642 2121 0.70 [0.63, 0.77] + + 280 1523 382 1492 0.72 [0.63, 0.82] + + + 20 215 78 207 0.25 [0.16, 0.39] + + + + 156 423 182 422 0.86 [0.72, 1.01] + <t< td=""></t<> |

Fig. 6. Summary of meta-analyses comparing alternative non-invasive respiratory support strategies versus CPAP for preterm infants after extubation.

3) Extubation in prone vs supine position to improve cardiorespiratory stability during extubation

During extubation.

1) Use of *PrePAP*, i.e. continuous positive distending pressure during the extubation procedure in order to stabilize the nasopharynx and reduce handling during the critical extubation period.

Post-extubation.

- 1) Investigation of a higher CPAP vs NIPPV after extubation (to determine whether the increased MAP or the peak inspiratory pressures are crucial for extubation success)
- 2) Investigate NIV-NAVA as a method to synchronize non-invasive ventilation after extubation with spontaneous breaths
- In the future, possibly investigate a synchronized nHFOV-NIPPV combination

6. Summary and recommendations

There are still many gaps in our knowledge regarding the ideal mode of respiratory support after extubation of newborn infants. However, based on the available data from RCTs, the following recommendations can be made.

- 1) Continuous positive airway pressure support (CPAP) remains the standard of care in the postextubation period. There is a considerable amount of evidence indicating its safety and effectiveness and most centres are experienced in its use. Thus, CPAP should be used for children \geq 28 weeks' gestational age and without prior cardiorespiratory difficulties. If no alternative mode of respiratory support is available, CPAP may be used in smaller infants as well. Higher pressures of 9–11 cm H₂O appear safe and effective in the single trial testing their use in preterm infants <28 weeks' gestational age.
- 2) In our updated meta-analysis, high-flow therapy was associated with higher rates of respiratory failure than CPAP (Fig. 6). However, if backup CPAP is available, the reintubation rate was similar to CPAP in the last Cochrane review [24]. Thus, backup CPAP should always be available when high-flow therapy is used as post-extubation respiratory support in order to prevent reintubation. If CPAP is available, high-flow therapy can be chosen for more mature infants, particularly those >30 weeks with a fraction of inspired oxygen of less than 0.3 [36].

3) For high-risk infants <28 weeks' gestation or infants with expected cardiorespiratory instability, either NIPPV or nHFOV should be used as post-extubation respiratory support. Both modes showed an important reduction in reintubation rate when compared with CPAP in our updated meta-analysis (Fig. 6). The use of synchronized, ventilator-generated NIPPV may be the most effective mode to deliver positive pressure ventilation but there is only limited data from small studies and thus, results should be interpreted with caution. The use of nHFOV after extubation seems to confer the largest benefit for very preterm infants but clinical experience is limited in most centres.

Funding

None.

Declaration of competing interest

The authors have no conflicts of interest to declare.

Acknowledgements

None.

References

- Subramaniam P, Ho JJ, Davis PG. Prophylactic nasal continuous positive airway pressure for preventing morbidity and mortality in very preterm infants. Cochrane Database Syst Rev 2016:CD001243.
- [2] Dargaville PA, Gerber A, Johansson S, De Paoli AG, Kamlin COF, Orsini F, et al. Incidence and outcome of CPAP failure in preterm Infants. Pediatrics 2016;138: e20153985–e20153985. https://doi.org/10.1542/peds.2015-3985.
- [3] Klinger G, Sokolover N, Boyko V, Sirota L, Lerner-Geva L, Reichman B, et al. Perinatal risk factors for bronchopulmonary dysplasia in a national cohort of verylow-birthweight infants. Am J Obstet Gynecol 2013;208. https://doi.org/10.1016/ j.ajog.2012.11.026. 115.e1-9.
- [4] Isayama T, Iwami H, McDonald S, Beyene J. Association of noninvasive ventilation strategies with mortality and bronchopulmonary dysplasia among preterm infants: a systematic review and meta-analysis. JAMA 2016;316:611–24.
- [5] Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, et al. Bronchopulmonary dysplasia. Nat Rev Dis Prim 2019;5:78. https://doi.org/ 10.1038/s41572-019-0127-7.
- [6] Laughon MM, Langer JC, Bose CL, Smith PB, Ambalavanan N, Kennedy KA, et al. Prediction of bronchopulmonary dysplasia by postnatal age in extremely premature infants. Am J Respir Crit Care Med 2011;183:1715–22. https://doi.org/ 10.1164/rccm.201101-0055OC.
- [7] Ammari A, Suri M, Milisavljevic V, Sahni R, Bateman D, Sanocka U, et al. Variables associated with the early failure of nasal CPAP in very low birth weight infants. J Pediatr 2005;147:341–7. https://doi.org/10.1016/j.jpeds.2005.04.062.

- [8] Duara S, Silva Neto G, Claure N. Role of respiratory muscles in upper airway narrowing induced by inspiratory loading in preterm infants. J Appl Physiol 1994; 77:30–6. https://doi.org/10.1152/jappl.1994.77.1.30.
- Jobe AH, Ikegami M. Mechanisms initiating lung injury in the preterm. Early Hum Dev 1998;53:81–94. https://doi.org/10.1016/s0378-3782(98)00045-0.
- [10] Riedel T, Kyburz M, Latzin P, Thamrin C, Frey U. Regional and overall ventilation inhomogeneities in preterm and term-born infants. Intensive Care Med 2009;35: 144–51. https://doi.org/10.1007/s00134-008-1299-x.
- [11] Cannavò L, Perrone S, Viola V, Marseglia L, Di Rosa G, Gitto E. Oxidative stress and respiratory diseases in preterm newborns. Int J Mol Sci 2021:22. https://doi.org/ 10.3390/ijms222212504.
- [12] Smitthimedhin A, Whitehead M, Bigdeli M, Nino G, Perez G, Otero H. MRI determination of volumes for the upper airway and pharyngeal lymphoid tissue in preterm and term infants. Clin Imaging 2018;50. https://doi.org/10.1016/J. CLINIMAG.2017.12.010.
- [13] Plastina L, Gaertner VD, Waldmann AD, Thomann J, Bassler D, Rüegger CM. The DELUX study: development of lung volumes during extubation of preterm infants. Pediatr Res 2021;92:242–8. https://doi.org/10.1038/s41390-021-01699-w.
- [14] Bhatia R, Carlisle HR, Armstrong RK, Kamlin COF, Davis PG, Tingay DG. Extubation generates lung volume inhomogeneity in preterm infants. Arch Dis Child Fetal Neonatal 2022;107:82–6. https://doi.org/10.1136/archdischild-2021-321788.
- [15] Miller MJ, Carlo WA, Martin RJ. Continuous positive airway pressure selectively reduces obstructive apnea in preterm infants. J Pediatr 1985;106:91–4. https:// doi.org/10.1016/s0022-3476(85)80475-3.
- [16] Mueller SM, Ackermann BW, Martin S, Seifert K, Mohr A, Alali W, et al. Incidence of intermittent hypoxemia increases during clinical care and parental touch in extremely preterm infants. Neonatology 2023;120:102–10. https://doi.org/ 10.1159/000527725.
- [17] Davis PG, Henderson-Smart DJ. Nasal continuous positive airways pressure immediately after extubation for preventing morbidity in preterm infants. Cochrane Database Syst Rev 2003:CD000143. https://doi.org/10.1002/14651858. CD000143.
- [18] Shalish W, Kanbar L, Kovacs L, Chawla S, Keszler M, Rao S, et al. The impact of time interval between extubation and reintubation on death or bronchopulmonary dysplasia in extremely preterm infants. J Pediatr 2019;205:70–76.e2. https://doi. org/10.1016/j.jpeds.2018.09.062.
- [19] Manley BJ, Doyle LW, Owen LS, Davis PG. Extubating extremely preterm infants: predictors of success and outcomes following failure. J Pediatr 2016;173:45–9. https://doi.org/10.1016/j.jpeds.2016.02.016.
- [20] Ramaswamy VV, More K, Roehr CC, Bandiya P, Nangia S. Efficacy of noninvasive respiratory support modes for primary respiratory support in preterm neonates with respiratory distress syndrome: systematic review and network meta-analysis. Pediatr Pulmonol 2020;55:2940–63. https://doi.org/10.1002/ppul.25011.
- [21] Rüegger CM, Owen LS, Davis PG. Nasal intermittent positive pressure ventilation for neonatal respiratory distress syndrome. Clin Perinatol 2021;48:725–44. https://doi.org/10.1016/j.clp.2021.07.004.
- [22] Waitz M, Mense L, Kirpalani H, Lemyre B. Nasal intermittent positive pressure ventilation for preterm neonates: synchronized or not? Clin Perinatol 2016;43: 799–816. https://doi.org/10.1016/j.clp.2016.07.013.
- [23] Goel D, Oei JL, Smyth J, Schindler T. Diaphragm-triggered non-invasive respiratory support in preterm infants. Cochrane Database Syst Rev 2020;3: CD012935. https://doi.org/10.1002/14651858.CD012935.pub2.
- [24] Wilkinson D, Andersen C, O'Donnell CPF, De Paoli AG, Manley BJ. High flow nasal cannula for respiratory support in preterm infants. Cochrane Database Syst Rev 2016;2:CD006405. https://doi.org/10.1002/14651858.CD006405.pub3.
- [25] Wilkinson DJ, Andersen CC, Smith K, Holberton J. Pharyngeal pressure with highflow nasal cannulae in premature infants. J Perinatol 2008;28:42–7. https://doi. org/10.1038/sj.jp.7211879.
- [26] De Luca D, Centorrino R. Nasal high-frequency ventilation. Clin Perinatol 2021;48: 761–82. https://doi.org/10.1016/j.clp.2021.07.006.
- [27] Gaertner VD, Waldmann AD, Davis PG, Bassler D, Springer L, Thomson J, et al. Transmission of oscillatory volumes into the preterm lung during noninvasive high-frequency ventilation. Am J Respir Crit Care Med 2021;203:998–1005. https://doi.org/10.1164/RCCM.202007-27010C.
- Fischer HS, Bohlin K, Bührer C, Schmalisch G, Cremer M, Reiss I, et al. Nasal high-frequency oscillation ventilation in neonates: a survey in five European countries. Eur J Pediatr 2015;174:465–71. https://doi.org/10.1007/s00431-014-2419-y.
 The Cochrane Collaboration Review Manager 2020;5 RevMan 5
- [29] The Cochrane Collaboration. Review Manager 2020;5. RevMan 5.
- [30] Lemyre B, Davis PG, De Paoli AG, Kirpalani H. Nasal intermittent positive pressure ventilation (NIPPV) versus nasal continuous positive airway pressure (NCPAP) for preterm neonates after extubation. Cochrane Database Syst Rev 2017;2:CD003212. https://doi.org/10.1002/14651858.CD003212.pub3.
- [31] Zhu X, Qi H, Feng Z, Shi Y, De Luca D. Nasal oscillation post-extubation (NASONE) study group. Noninvasive high-frequency oscillatory ventilation vs nasal continuous positive airway pressure vs nasal intermittent positive pressure ventilation as postextubation support for preterm neonates in China: a randomized clinical trial. JAMA Pediatr 2022;176:551–9. https://doi.org/10.1001/ jamapediatrics.2022.0710.
- [32] Kitsommart R, Kalyn A, Al-Saleem N, Rnc MJ, Sant GM. Levels of nasal CPAP applied during the immediate post- extubation phase: a randomized controlled pilot trial. EJ Neonatol Res 2013;3:2–10.
- [33] Kidman AM, Manley BJ, Boland RA, Malhotra A, Donath SM, Davis PG, et al. Protocol for a randomised controlled trial comparing two CPAP levels to prevent extubation failure in extremely preterm infants. BMJ Open 2021;11:e045897. https://doi.org/10.1136/bmjopen-2020-045897.

- [34] Kidman A, Manley B, Malhotra A, Beker F, Davis P, Bhatia B. Extubating extremely preterm infants: results of ECLAT. Pediatr. Acad. Soc. Annu. Meet. 2023.
- [35] Lemyre B, Laughon M, Bose C, Davis PG. Early nasal intermittent positive pressure ventilation (NIPPV) versus early nasal continuous positive airway pressure (NCPAP) for preterm infants. Cochrane Database Syst Rev 2016;12:CD005384. https://doi.org/10.1002/14651858.CD005384.pub2.
- [36] Yoder BA, Manley B, Collins C, Ives K, Kugelman A, Lavizzari A, et al. Consensus approach to nasal high-flow therapy in neonates. J Perinatol 2017;37:809–13. https://doi.org/10.1038/jp.2017.24.
- [37] Khorana M, Paradeevisut H, Sangtawesin V, Kanjanapatanakul W, Chotigeat U, Ayutthaya JKN. A randomized trial of non-synchronized Nasopharyngeal Intermittent Mandatory Ventilation (nsNIMV) vs. Nasal Continuous Positive Airway Pressure (NCPAP) in the prevention of extubation failure in pre-term < 1,500 grams. J Med Assoc Thai 2008;91(Suppl 3):S136–42.
- [38] O'Brien K, Campbell C, Brown L, Wenger L, Shah V. Infant flow biphasic nasal continuous positive airway pressure (BP- NCPAP) vs. infant flow NCPAP for the facilitation of extubation in infants' ≤ 1,250 grams: a randomized controlled trial. BMC Pediatr 2012;12:43. https://doi.org/10.1186/1471-2431-12-43.
- [39] Kahramaner Z, Erdemir A, Turkoglu E, Cosar H, Sutcuoglu S, Ozer EA. Unsynchronized nasal intermittent positive pressure versus nasal continuous positive airway pressure in preterm infants after extubation. J Matern Fetal Neonatal Med 2014;27:926–9. https://doi.org/10.3109/14767058.2013.846316.
- [40] Jasani B, Nanavati R, Kabra N, Rajdeo S, Bhandari V. Comparison of nonsynchronized nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as post-extubation respiratory support in preterm infants with respiratory distress syndrome: a randomized controlled trial. J Matern Neonatal Med 2016;29:1546–51. https://doi.org/10.3109/ 14767058.2015.1059809.
- [41] Komatsu DFR, Diniz EM de A, Ferraro AA, Ceccon MEJR, Vaz FAC. Randomized controlled trial comparing nasal intermittent positive pressure ventilation and nasal continuous positive airway pressure in premature infants after tracheal extubation. Rev Assoc Med Bras 2016;62:568–74. https://doi.org/10.1590/1806-9282.62.06.568.
- [42] Victor S, Roberts SA, Mitchell S, Aziz H, Lavender T, Extubate Trial Group. Biphasic positive airway pressure or continuous positive airway pressure: a randomized trial. Pediatrics 2016;138. https://doi.org/10.1542/peds.2015-4095.
- [43] Esmaeilnia T, Nayeri F, Taheritafti R, Shariat M, Moghimpour-Bijani F. Comparison of complications and efficacy of NIPPV and nasal CPAP in preterm infants with RDS. Iran J Pediatr 2016;26. https://doi.org/10.5812/ijp.2352.
- [44] Ribeiro SNS, Fontes MJF, Bhandari V, Resende CB, Johnston C. Noninvasive ventilation in newborns ≤ 1,500 g after tracheal extubation: randomized clinical trial. Am J Perinatol 2017;34:1190–8. https://doi.org/10.1055/s-0037-1602141.
- [45] Estay AS, Mariani GL, Alvarez CA, Milet B, Agost D, Avila CP, et al. Randomized controlled trial of nonsynchronized nasal intermittent positive pressure ventilation versus nasal CPAP after extubation of VLBW infants. Neonatology 2020;117:193–9. https://doi.org/10.1159/000506164.
- [46] Pan R, Chen G-Y, Wang J, Zhou Z-X, Zhang P-Y, Chang L-W, et al. Bi-Level nasal positive airway pressure (BiPAP) versus nasal continuous positive airway pressure (CPAP) for preterm infants with birth weight less than 1500 g and respiratory distress syndrome following INSURE treatment: a two-center randomized controlled trial. Curr Med Sci 2021;41:542–7. https://doi.org/10.1007/s11596-021-2372-8.
- [47] Li Y, Wei Q, Zhao D, Mo Y, Yao L, Li L, et al. Non-invasive high-frequency oscillatory ventilation in preterm infants after extubation: a randomized, controlled trial. J Int Med Res 2021;49:300060520984915. https://doi.org/ 10.1177/0300060520984915.
- [48] Yuan G, Liu H, Wu Z, Chen X. Evaluation of three non-invasive ventilation modes after extubation in the treatment of preterm infants with severe respiratory distress syndrome. J Perinatol 2022;42:1238–43. https://doi.org/10.1038/s41372-022-01461-v.
- [49] El-Farrash RA, DiBlasi RM, Abdel-Aziz EA, El-Tahry AM, Eladawy MS, Tadros MA, et al. Postextubation noninvasive ventilation in respiratory distress syndrome: a randomized controlled trial. Am J Perinatol 2022;29:1577–85. https://doi.org/ 10.1055/s-0041-1723999.
- [50] Friedlich P, Lecart C, Posen R, Ramicone E, Chan L, Ramanathan R. A randomized trial of nasopharyngeal-synchronized intermittent mandatory ventilation versus nasopharyngeal continuous positive airway pressure in very low birth weight infants after extubation. J Perinatol 1999;19:413–8. https://doi.org/10.1038/sj. jp.7200205.
- [51] Barrington KJ, Bull D, Finer NN. Randomized trial of nasal synchronized intermittent mandatory ventilation compared with continuous positive airway pressure after extubation of very low birth weight infants. Pediatrics 2001;107: 638–41. https://doi.org/10.1542/peds.107.4.638.
- [52] Khalaf MN, Brodsky N, Hurley J, Bhandari V. A prospective randomized, controlled trial comparing synchronized nasal intermittent positive pressure ventilation versus nasal continuous positive airway pressure as modes of extubation. Pediatrics 2001;108:13–7. https://doi.org/10.1542/peds.108.1.13.
- [53] Moretti C, Giannini L, Fassi C, Gizzi C, Papoff P, Colarizi P. Nasal flowsynchronized intermittent positive pressure ventilation to facilitate weaning in very low-birthweight infants: unmasked randomized controlled trial. Pediatr Int 2008;50:85–91. https://doi.org/10.1111/j.1442-200X.2007.02525.x.
- [54] Gao W-W, Tan S-Z, Chen Y-B, Zhang Y, Wang Y. [Randomized trial of nasal synchronized intermittent mandatory ventilation compared with nasal continuous positive airway pressure in preterm infants with respiratory distress syndrome]. Zhong Guo Dang Dai Er Ke Za Zhi 2010;12:524–6.

- [55] Ding F, Zhang J, Zhang W, Zhao Q, Cheng Z, Wang Y, et al. Clinical study of different modes of non-invasive ventilation treatment in preterm infants with respiratory distress syndrome after extubation. Front Pediatr 2020;8. https://doi. org/10.3389/FPED.2020.00063.
- [56] Shin SH, Shin SH, Kim SH, Song IG, Jung YH, Kim E-K, et al. Noninvasive neurally adjusted ventilation in postextubation stabilization of preterm infants: a randomized controlled study. J Pediatr 2022;247:53–59.e1. https://doi.org/ 10.1016/j.jpeds.2022.04.025.
- [57] Kirpalani H, Millar D, Lemyre B, Yoder BA, Chiu A, Roberts RS, et al. A trial comparing noninvasive ventilation strategies in preterm infants. N Engl J Med 2013;369:611–20. https://doi.org/10.1056/NEJMoa1214533.
- [58] Collins CL, Holberton JR, Barfield C, Davis PG. A randomized controlled trial to compare heated humidified high-flow nasal cannulae with nasal continuous positive airway pressure postextubation in premature infants. J Pediatr 2013;162: 949–954.e1. https://doi.org/10.1016/j.jpeds.2012.11.016.
- [59] Manley BJ, Owen LS, Doyle LW, Andersen CC, Cartwright DW, Pritchard MA, et al. High-flow nasal cannulae in very preterm infants after extubation. N Engl J Med 2013;369:1425–33. https://doi.org/10.1056/NEJMoa1300071.
- [60] Soonsawad S, Swatesutipun B, Limrungsikul A, Nuntnarumit P. Heated humidified high-flow nasal cannula for prevention of extubation failure in preterm infants. Indian J Pediatr 2017;84:262–6. https://doi.org/10.1007/s12098-016-2280-2.
- [61] Elkhwad M, Dako J, Jennifer G, Harriet F, Anand K. Randomized control trial: heated humidity high flow nasal cannula in comparison with NCPAP in the management of RDS in extreme low birth infants in immediate post extubation period. Neonatal Pediatr Med 2017;3:1–6. https://doi.org/10.4172/2572-4983.1000121.
- [62] Campbell DM, Shah PS, Shah V, Kelly EN. Nasal continuous positive airway pressure from high flow cannula versus Infant Flow for Preterm infants. J Perinatol 2006;26:546–9. https://doi.org/10.1038/sj.jp.7211561.
- [63] Yoder BA, Stoddard RA, Li M, King J, Dirnberger DR, Abbasi S. Heated, humidified high-flow nasal cannula versus nasal CPAP for respiratory support in neonates. Pediatrics 2013;131:e1482–90. https://doi.org/10.1542/peds.2012-2742.
- [64] Peirovifar A, Mostafa Gharehbaghi M, Khogasteh S. Risk factors contributing the failure of extubation after surfactant administration with INSURE method. Eur J Anaesthesiol 2014;31:164.
- [65] Liu C. Collaborative Group for the Multicenter Study on Heated Humidified Highflow Nasal Cannula Ventilation. Efficacy and safety of heated humidified high-flow nasal cannula for prevention of extubation failure in neonates. Zhonghua Er Ke Za Zhi 2014;52:271–6.
- [66] Chen J, Gao WW, Xu F, Du LL, Zhang T, Ling X, et al. [Comparison of clinical efficacy of heated humidified high flow nasal cannula versus nasal continuous positive airway pressure in treatment of respiratory distress syndrome in very low birth weight infants]. Zhong Guo Dang Dai Er Ke Za Zhi 2015;17:847–51.
- [67] Kadivar MM, Mosayebi ZM, Razi NM, Nariman SM, Sangsari RM. High flow nasal cannulae versus nasal continuous positive airway pressure in neonates with

respiratory distress syndrome managed with INSURE method: a randomized clinical trial. Iran J Med Sci 2016;41:494–500.

- [68] Singh S, Ananthan A, Nanavati R. Post-INSURE administration of heated humidified high-flow therapy versus nasal continuous positive airway pressure in preterm infants more than 28 Weeks gestation with respiratory distress syndrome: a randomized non-inferiority trial. J Trop Pediatr 2022;68. https://doi.org/ 10.1093/trope//fmac062.
- [69] Kang W, Xu B, Liu D, Zhang Y, Guo J, Li Z, et al. [Efficacy of heated humidified high-flow nasal cannula in preterm infants aged less than 32 weeks after ventilator weaning]. Zhong Guo Dang Dai Er Ke Za Zhi 2016;18. https://doi.org/10.7499/J. ISSN.1008-8830.2016.06.004.
- [70] Chen J, Lin Y, Du L, Kang M, Chi X, Wang Z, et al. The comparison of HHHFNC and ncpap in extremely low-birth-weight preterm infants after extubation: a singlecenter randomized controlled trial. Front Pediatr 2020;8. https://doi.org/10.3389/ FPED.2020.00250.
- [71] Uchiyama A, Okazaki K, Kondo M, Oka S, Motojima Y, Namba F, et al. Randomized controlled trial of high-flow nasal cannula in preterm infants after extubation. Pediatrics 2020;146. https://doi.org/10.1542/peds.2020-1101.
- [72] Lou W, Zhang W. Noninvasive high-frequency oscillatory ventilation versus nasal continuous positive airway pressure in premature infants with respiratory distress syndrome after weaning: a randomized controlled trial. Guangdong Med J 2017; 38:2037–40.
- [73] Chen L, Wang L, Ma J, Feng Z, Li J, Shi Y. Nasal high-frequency oscillatory ventilation in preterm infants with respiratory distress syndrome and ARDS after extubation: a randomized controlled trial. Chest 2019;155:740–8. https://doi.org/ 10.1016/j.chest.2019.01.014.
- [74] Wang Z, Gao W, Shen Y, et al. Effects of noninvasive high frequency oscillatory ventilation for respiratory distress syndrome in very low birth weight preterm infants after extubation - CNKI. Guangdong Med J 2019;10:1391–5. https://doi. org/10.13820/j.cnki.gdyx.20186640.
- [75] Seth S, Saha B, Saha AK, Mukherjee S, Hazra A. Nasal HFOV versus nasal IPPV as a post-extubation respiratory support in preterm infants-a randomised controlled trial. Eur J Pediatr 2021;180:3151–60. https://doi.org/10.1007/s00431-021-04084-1.
- [76] Jia Y, Zhao G, Zhang K. Effect of different ventilation modes on low birth weight premature infants with respiratory distress syndrome after extubation and weaning. Chinese J Pract Med 2021. https://doi.org/10.3760/cma.j.cn115689-20210216-00757.
- [77] Zhuang Y, Gao X, Wu Y, Xiong Y, Zhou D. Application of noninvasive high-frequency oscillatory ventilation after extubation in preterm infants with severe bronchopulmonary dysplasia. Chin J Neonatol 2021;36:2096–932. https://doi.org/10.3760/cma.j.issn.2096-2932.2021.02.008.
- [78] Zhang R, Shen L, Wen J, Ye L, Liang Z, Han F. Application of non-invasive high frequency oscillation ventilation after extubation in persistent pulmonary hypertension of newborn. Shenzhen J Integr Tradit Chinese West Med 2022;32: 101–3. https://doi.org/10.16458/j.cnki.1007-0893.2022.01.032.